替格瑞洛的安全性分析

摘要

随着PLATO研究的公布,替格瑞洛因其良好的药理学特性及显著的临床获益被欧美指南推荐为一线或首选的抗血小板药物治疗急性冠状动脉综合征,但是替格瑞洛增加了出血风险.而出血发生率的增高与患者不良临床预后相关.本文对替格瑞洛的药动学、药效学、安全性和耐受性等方面进行综述.%As the publication of PLATO study,ticagrelor has been recommended as the preferred antiplatelet drug for acute coronary syndrome by European and American guidelines because of the excellent pharmacological properties and significant clinical benefits.But ticagrelor increases the risk of bleeding.Many clinical trials has demonstrated that bleeding is strongly associated with poor prognosis.This review discussed the pharmacokinetic and pharmacodynamics properties of ticagrelor,as well as the safety and tolerability.